Wandercraft
- Total funding
- $142M+ raised, incl. $75M Series D (equity and debt)
- Valuation
- —
- Founded
- 2012
- Headquarters
- Paris, France / New York, USA
- Segment
- Powered – Full Lower Body (self-balancing)
- Status
- Private
- Target market
- Medical/Rehabilitation (SCI, stroke, paraplegia)
- Founders
- Nicolas Simon, Matthieu Masselin, Alexandre Boulanger, Jean-Louis Constanza
- Website
- en.wandercraft.eu
Latest research
Updated Sep 8, 2026Wandercraft raised $75M in equity and debt as part of its Series D, bringing total funding above $142M. The money funds the market launch of Eve, a self-balancing personal exoskeleton, wider clinical adoption of the Atalante X rehabilitation system, and development of its Calvin-40 humanoid.
- $75M Series D in equity and debt
- $142M+ raised in total
- Atalante X is FDA-cleared with 90+ hospital deployments
- Also developing Calvin-40, a humanoid robot — the reason this company previously appeared twice in this directory
Notes
Atalante X: FDA-cleared, world's first self-balancing exoskeleton. 90+ hospital deployments. Raised $142M+. | UPDATE: $75M Series D (Jun 2025) brought cumulative funding to $137M+ (Renault Group, Bpifrance PSIM, Teampact Ventures, Quadrant Management). New products: Eve (home-care exosuit, NVIDIA Jetson edge compute, 2026 US launch planned) and Calvin-40 (humanoid industrial robot for high-risk manufacturing, runs NVIDIA Isaac GR00T + Jetson) — company has expanded beyond pure exoskeletons into humanoid robotics via a technical cooperation agreement with NVIDIA.
Backed by
No investors disclosed for Wandercraft (funding listed as "$142M+ raised, incl. $75M Series D (equity and debt)"). Browse all tracked investors →